[{"address1": "321 Summer Street", "address2": "Suite 400", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857 330 4340", "website": "https://www.inozyme.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 67, "companyOfficers": [{"maxAge": 1, "name": "Dr. Douglas A. Treco Ph.D.", "age": 66, "title": "CEO & Chairman", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 591875, "exercisedValue": 0, "unexercisedValue": 116098}], "auditRisk": 6, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.21, "open": 1.21, "dayLow": 1.18, "dayHigh": 1.85, "regularMarketPreviousClose": 1.21, "regularMarketOpen": 1.21, "regularMarketDayLow": 1.18, "regularMarketDayHigh": 1.85, "payoutRatio": 0.0, "beta": 1.388, "forwardPE": -1.0, "volume": 8017499, "regularMarketVolume": 8017499, "averageVolume": 634093, "averageVolume10days": 1216830, "averageDailyVolume10Day": 1216830, "bid": 1.31, "ask": 1.92, "bidSize": 2, "askSize": 2, "marketCap": 104069128, "fiftyTwoWeekLow": 0.721, "fiftyTwoWeekHigh": 6.24, "fiftyDayAverage": 1.0334, "twoHundredDayAverage": 3.1421, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 37855120, "profitMargins": 0.0, "floatShares": 35838322, "sharesOutstanding": 64240200, "sharesShort": 4423769, "sharesShortPriorMonth": 3989178, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.0689, "heldPercentInsiders": 0.01222, "heldPercentInstitutions": 0.92285, "shortRatio": 9.37, "shortPercentOfFloat": 0.0744, "impliedSharesOutstanding": 64240200, "bookValue": 0.9, "priceToBook": 1.8000001, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -102024000, "trailingEps": -1.62, "forwardEps": -1.62, "enterpriseToEbitda": -0.367, "52WeekChange": -0.66803277, "SandP52WeekChange": 0.09765589, "quoteType": "EQUITY", "currentPrice": 1.62, "targetHighPrice": 23.0, "targetLowPrice": 7.0, "targetMeanPrice": 13.5, "targetMedianPrice": 13.5, "recommendationKey": "none", "numberOfAnalystOpinions": 8, "totalCash": 113087000, "totalCashPerShare": 1.76, "ebitda": -103288000, "totalDebt": 46873000, "quickRatio": 3.35, "currentRatio": 3.56, "debtToEquity": 81.059, "returnOnAssets": -0.40131, "returnOnEquity": -1.02896, "freeCashflow": -55088500, "operatingCashflow": -91907000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "INZY", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Inozyme Pharma, Inc.", "longName": "Inozyme Pharma, Inc.", "exchange": "NMS", "messageBoardId": "finmb_568596329", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "regularMarketChangePercent": 33.884293, "regularMarketPrice": 1.62, "marketState": "CLOSED", "fiftyTwoWeekLowChangePercent": 1.2468793, "fiftyTwoWeekRange": "0.721 - 6.24", "fiftyTwoWeekHighChange": -4.62, "fiftyTwoWeekHighChangePercent": -0.74038464, "fiftyTwoWeekChangePercent": -66.803276, "earningsTimestamp": 1741609800, "earningsTimestampStart": 1746448200, "earningsTimestampEnd": 1746793800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.62, "epsForward": -1.62, "epsCurrentYear": -1.105, "priceEpsCurrentYear": -1.4660634, "fiftyDayAverageChange": 0.58659995, "fiftyDayAverageChangePercent": 0.5676407, "twoHundredDayAverageChange": -1.5221001, "twoHundredDayAverageChangePercent": -0.48442125, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-07-24", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1595597400000, "esgPopulated": false, "postMarketChangePercent": -3.08642, "postMarketPrice": 1.57, "postMarketChange": -0.05, "regularMarketChange": 0.40999997, "regularMarketDayRange": "1.18 - 1.85", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 634093, "fiftyTwoWeekLowChange": 0.899, "corporateActions": [], "postMarketTime": 1746230153, "regularMarketTime": 1746216001, "displayName": "Inozyme Pharma", "trailingPegRatio": null, "__fetch_time": "2025-05-03"}]